Healthy volunteers needed to test aramchol absorption

NCT ID NCT07251712

Recruiting now Knowledge-focused Sponsor: Galmed Pharmaceuticals Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing how the body absorbs a single dose of aramchol, a drug being studied for liver disease. Researchers will give 32 healthy volunteers two different single doses of aramchol meglumine tablets and measure drug levels in their blood. The goal is to understand how much drug gets into the bloodstream and how long it stays there.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Aramchol (aramchol meglumine tablet)

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hammersmith Medicines Research (HMR)
RECRUITING

London, NW10 7EW, United Kingdom

Contact Email: •••••@•••••